MDT Session: Immunotherapy-Based Combination Approaches in HCC: Integrating Personalized Treatment Decisions

This industry session is organised independently from the scientific programme and is delivered by one of the ILCA AC2026 sponsors.

Moderators:

Prof. Lynn Jeanette Savic, University Hospital Magdeburg

Lorenza Rimassa, Humanitas University - IRCCS Humanitas Research Hospital

Speakers:

Prof. Maxime Ronot, Beaujon, Paris

Prof. Josep M. Llovet, University Hospital Barcelona

Prof. David Pinato, Imperial College London

Prof. Lynn Jeanette Savic, University Hospital Magdeburg

Program:

Opening | Savic

Talk 1 (8’) | From bench to bedside: Immunobiological Responses and the Molecular Rationale for Combining TACE with Immunotherapy

Lynn Savic (GER)

Talk 2 (17’)| From Trial to Treatment: Phase III Evidence and Practical Implementation in Daily Clinical Practice

M. Llovet (SP, US)

Talk 3 (21’) Interactive MDT Discussion: ​A Clinical case in three steps: Who Is the Right Candidate for TACE–Immunotherapy Combination?

Step 1: Early transition from TACE to combination therapy, M Ronot​

Step 2: Beyond-stage migration and treatment intensification in borderline candidates: balancing efficacy, liver function, and safety – D. Pinato​

Step 3: What Do the Evidence and Guidelines Tell Us? Integrating RCT Data and Guideline Recommendations into Clinical Decision-Making – J. Llovet, with faculty panel and audience discussion​

Talk 4 (8’)| The Immunotherapy–TACE Focus Group Initiative: Building the Foundation for Consensus and Standardization Lynn Savic

Closing | Moderator : Savic